Overview of Tankyrases, a new target for anti-tumor drugs, and its targeted drug development.
ESMO 2020: Positive progress has been made in the treatment of relapsed cervical cancer with antibody-drug couple Tisotumab vedotin.
Fda priority reviews applications for peptide-drug melflufen to treat refractic multiple myeloma.
Wanchun Pharmaceutical First In Class's new drug, Punabrin, has been recognized by the FDA as a breakthrough therapy.
260 million! Hesco transferred its interest in a new drug for prostate cancer to Haitron Pharmaceuticals.
Gan Li Pharmaceutical CDK4/6 inhibitors are eligible for FDA orphan drugs to treat malignant gliomas.
Cell Death Differ: AQP1 may be used as an indicator for predicting the sensitivity of cycloviral drugs in breast cancer patients.
New drugs that are not on the market are available here.
of high-efficiency broad-spectrum anti-human and veterinary infectious diseases new drugs.
Antibody drug adjulycturing drug Vic-) quertoju monoantitor Duocarmazine to treat HER2-positive
AJOG: CD70 Antibody-Drug Coupler is expected to be a target drug for uterine smooth muscoma.
The world's first oral drug to improve colonoscopy results, Methylene Blue MMX, has been approved in Europe.
Estrogen-like agonist TTC-352, an anti-breast cancer drug with therapeutic potential.
CELL: Single-cell sequencing reveals how drug therapy induced the evolution of lung cancer in humans.
Four-specific antibodies! Baili Pharmaceuticals is once again in the study of anti-cancer drugs approved clinically.
Jingding Pharmaceuticals Global Patient Advisory Committee landed in China to promote patient-centered drug development.
It is worth exploring to promote drug counterfeiting and direct criminalization.
Clin Cancer Res: Immune checkpoint target drug MEDI0562 to treat advanced solid tumors.
Focus on improving the development of new drugs! Qingpu Bio successfully obtained nearly 50 million yuan pre-A round financing.
The anti-COVID-19 monoclonal antibody candidate drug CT-P59:Phase I clinical trials obtained positive results.